减少婴儿疫苗接种疼痛:对ShotBlocker和手动压力的影响进行随机对照试验
Şeyma Kışlalı Taş1, Dilek Sari2, Nihal Taşkıran3
1Manisa Soma No. 5 Family Health Center, Manisa, Turkey.
Clinical pediatrics
|October 29, 2025
概括
无论是ShotBlocker还是手动压力都没有减少肺炎球菌合疫苗 (PCV) 射击期间婴儿的疼痛. 需要进一步的研究,以便在接种疫苗期间有效地治疗婴儿疼痛.
科学领域:
- 儿科 儿科 儿科
- 免疫学 免疫学 免疫学
- 疼痛管理 疼痛管理
背景情况:
- 婴儿接种疫苗可能是一个痛苦的经历.
- 在免疫接种期间,有效的非药物疼痛管理策略对婴儿至关重要.
研究的目的:
- 评估ShotBlocker和手动压力在四个月大婴儿的肺炎球菌联合疫苗 (PCV) 施用期间减轻疼痛的疗效.
- 为了比较接受PCV与ShotBlocker,手动压力或没有干预的婴儿之间的疼痛得分.
主要方法:
- 一项随机的实验研究,涉及102名接受PCV的4个月大的婴儿.
- 参与者被随机分配到ShotBlocker,手动压力或对照组 (每组34名婴儿).
- 使用新生儿婴儿疼痛量表 (NIPS) 和视频记录来评估疼痛.
主要成果:
- 在ShotBlocker,手动压力和对照组之间没有观察到NIPS得分的统计学上显著差异 (F = 0.789,P > .05).
- 在这个婴儿队列中,无论是ShotBlocker还是手动压力都没有在PCV给药期间减轻疼痛的有效性.
结论:
- 目前的非药物方法,如ShotBlocker和手动压力,对于在PCV疫苗接种期间在4个月大的婴儿中减轻疼痛是无效的.
- 需要探索和开发用于婴儿免疫接种的替代性,特定的非药物疼痛管理策略.
相关概念视频
01:11Blinding
3.8K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
3.8K
01:51Vaccinations
51.2K
Overview
51.2K
01:16Local Anesthetics: Clinical Application as Intravenous Regional Anesthesia
1.2K
Intravenous regional anesthesia or the Bier block technique is used to anesthetize a specific limb or extremity. It uses exsanguinated or blood-drained vessels to transport local anesthetics or LAs to the peripheral nerve trunks. Lidocaine without vasoconstrictors like epinephrine is most commonly used for this technique. Other drugs used are prilocaine, ropivacaine, and chloroprocaine. Bupivacaine is not recommended for this technique due to its high cardiac toxicity.
One of the advantages of...
One of the advantages of...
1.2K
01:29Drug Dosing: Infants and Children
248
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
248